BDBM277379 US10072025, Example 3-13::US10072025, Example 3-14::US10072025, Example 3-15::US10072025, Example 3-16::tert-butyl 4-[3-({4-[(2,3- dimethylmorpholin-4- yl)carbonyl]-3- methylphenyl}amino)-4- oxo-4,5-dihydro-1H- pyrazolo[4,3-c] pyridin-1- yl]-4-ethylpiperidine-1- carboxylate (Peak 2, separated by mass triggered reverse phase HPLC (ACN/water with 0.1% NH4OH modifier) then was separated by SFC using Phenomenex Lux-4 column, eluting with 40% methanol +0.25% dimethyl ethyl amine in CO2, retention time peak B: 10.2 minutes.)

SMILES CCC1(CCN(CC1)C(=O)OC(C)(C)C)n1nc(Nc2ccc(C(=O)N3CCOC(C)C3C)c(C)c2)c2c1cc[nH]c2=O

InChI Key InChIKey=HCUJMXUNTUJCQO-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 277379   

TargetTyrosine-protein kinase JAK2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 1.04nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 1.07nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 1.76nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 1.80nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 1.87nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 2.10nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 2.88nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM277379(US10072025, Example 3-16 | US10072025, Example 3-1...)
Affinity DataIC50: 3.53nMT: 2°CAssay Description:The ability of compounds to inhibit the activity of JAK1, JAK2, JAK3, and Tyk2 was measured using a recombinant purified GST-tagged catalytic domain ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/21/2018
Entry Details
US Patent